Literature DB >> 12649391

Ambient temperature influences core body temperature response in rat lines bred for differences in sensitivity to 8-hydroxy-dipropylaminotetralin.

Andrea C Nicholas1, Lewis S Seiden.   

Abstract

Agonist-induced decrease in core body temperature has commonly been used as a measure of serotonin1A (5-HT(1A)) receptor sensitivity in mood disorder. The thermoregulatory basis for 5-HT(1A) receptor agonist-induced temperature responses in humans and rats remains unclear. Therefore, the influence of ambient temperature on 5-HT(1A) receptor-mediated decreases in core body temperature were measured in rat lines bred for high (HDS) or low (LDS) sensitivity to the selective 5-HT(1A) receptor agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT). HDS and LDS rats were injected with either saline, 0.25 or 0.50 mg/kg 8-OH-DPAT at ambient temperatures of 10.5, 24, 30, or 37.5 degrees C, and core temperature was measured by radiotelemetry. For both lines, the thermic response to acute 8-OH-DPAT was greatest at 10.5 degrees C and decreased in magnitude as ambient temperature increased to 30 degrees C, consistent with hypothermia. HDS rats displayed a greater hypothermic response than LDS rats at 10.5, 24, and 30 degrees C. At 37.5 degrees C, LDS rats showed a lethal elevation of temperature in response to 0.50 mg/kg 8-OH-DPAT. All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation. Following repeated injection of 8-OH-DPAT, the magnitude of the hypothermic response decreased in both lines at 10.5 degrees C, but increased in HDS rats treated with 0.50 mg/kg 8-OH-DPAT at 30 and 37.5 degrees C. This pattern was reversed in HDS rats following 8-OH-DPAT challenge at 24 degrees C, suggesting that a compensatory thermoregulatory response accounts for changes in the hypothermic response to chronic 8-OH-DPAT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649391     DOI: 10.1124/jpet.102.045088

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan
Journal:  Ann Forensic Res Anal       Date:  2017-03-07

2.  The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature.

Authors:  Kathryn S Saadat; Esther O'shea; M Isabel Colado; J Martin Elliott; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2005-01-14       Impact factor: 4.530

3.  A positive relationship between ambient temperature and bipolar disorder identified using a national cohort of psychiatric inpatients.

Authors:  Tzu-I Sung; Mu-Jean Chen; Huey-Jen Su
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-07-05       Impact factor: 4.328

4.  Vapor inhalation of cannabidiol (CBD) in rats.

Authors:  Mehrak Javadi-Paydar; Kevin M Creehan; Tony M Kerr; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2019-07-20       Impact factor: 3.533

5.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

6.  5-Hydroxytryptamine 1A receptors inhibit cold-induced sympathetically mediated cutaneous vasoconstriction in rabbits.

Authors:  Y Ootsuka; W W Blessing
Journal:  J Physiol       Date:  2003-08-08       Impact factor: 5.182

7.  Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats.

Authors:  Ibrahim M Shokry; Connor J Shields; John J Callanan; Zhiyuan Ma; Rui Tao
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-05       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.